CoChat

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

BACKGROUND INCREASE was a randomised, placebo-controlled, phase 3 trial that evaluated inhaled treprostinil in patients with interstitial lung disease (ILD) and associated pulmonary hypertension. Treprostinil improved exercise capacity from baseline to week 16, assessed with the use of a 6-min walk test, compared with placebo. Improvements in forced vital capacity (FVC) were also reported. The aim of this post-hoc analysis was to further characterise the effects of inhaled treprostinil on FVC in the overall study population and in various subgroups of interest. METHODS In this post-hoc analysis, we evaluated FVC changes in the overall study population and in various subgroups defined by cause of disease or baseline clinical parameters. The study population included patients aged 18 years and older who had a diagnosis of ILD based on evidence of diffuse parenchymal lung disease on chest CT done within 6 months before random assignment (not centrally adjudicated). All analyses were done on the intention-to-treat population, defined as individuals who were randomly assigned and received at least one dose of study drug. The INCREASE study is registered with ClinicalTrials.gov, NCT02630316. FINDINGS Between Feb 3, 2017, and Aug 30, 2019, 326 patients were enrolled in the INCREASE trial. Inhaled treprostinil was associated with a placebo-corrected least squares mean improvement in FVC of 28·5 mL (SE 30·1; 95% CI -30·8 to 87·7; p=0·35) at week 8 and 44·4 mL (35·4; -25·2 to 114·0; p=…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(21)00165-x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 161

Metadata

Authors
Nathan, S. D., Waxman, A., Rajagopal, S., Case, A., Johri, S., DuBrock, H., De La Zerda, D. J., Sahay, S., King, C., Melendres-Groves, L., Smith, P., Shen, E., Edwards, L. D., Nelsen, A., & Tapson, V. F.
Affiliations
  • Inova Fairfax Hospital (US)
  • Brigham and Women's Hospital (US)
  • Duke Medical Center (US)
  • Piedmont HealthCare (US)
  • Mayo Clinic (US)
  • Houston Methodist (US)
  • University of New Mexico (US)
  • United Therapeutics (United States) (US)
  • Cedars-Sinai Medical Center (US)
Corresponding author
Nathan, Steven D
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2021-11
Volume
9
Issue
11
Pages
1266-1274
ISSN
2213-2600 (ISSN-L)
OpenAlex
W3176751071
Cited by
152
References
23
Citations by year
2026: 26 · 2025: 35 · 2024: 31 · 2023: 39 · 2022: 16 · 2021: 5
FWCI
14.71
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pharmaceuticals Bayer
  • GlaxoSmithKline
  • United Therapeutics Corporation
  • Boehringer Ingelheim
  • American College of Clinical Pharmacy
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords
inhaled treprostinil, interstitial lung disease, pulmonary hypertension, forced vital capacity, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, subgroup analysis, lung function decline, vasodilator therapy, exercise capacity, 6-minute walk test, subgroup heterogeneity, treatment effect heterogeneity
MeSH terms
Adolescent, Adult, Double-Blind Method, Humans, Hypertension, Pulmonary, Prospective Studies, Epoprostenol, Vital Capacity, Treatment Outcome, Lung Diseases, Interstitial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. https://app.cochat.ai/papers/10.1016/s2213-2600(21)00165-x
The paper
Nathan, S. D., Waxman, A., Rajagopal, S., Case, A., Johri, S., DuBrock, H., De La Zerda, D. J., Sahay, S., King, C., Melendres-Groves, L., Smith, P., Shen, E., Edwards, L. D., Nelsen, A., & Tapson, V. F. (2021). Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(21)00165-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.